1. Scrip
  2. >>Therapy Areas

Astellas to bring OSI fully into the fold by mid-2011

 
• By Ian Haydock

Astellas expects to complete the integration of its US acquisition OSI Pharmaceuticals by the end of June next year, by which time a number of restructuring moves associated with the transaction will have taken place.

Astellas expects to complete the integration of its US acquisition OSI Pharmaceuticals by the end of June next year, by which time a number of restructuring moves associated with the transaction will have taken place.

The Japanese firm paid around $4 billion for OSI when it closed a tender offer in June, after an occasionally...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapeutic Category

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.